Chara Biologics

Chara Biologics is a private U.S. regenerative medicine company focused on birth-tissue-derived biologic products marketed to healthcare providers and patients. The company was founded by Dr. Joy Kong and promotes proprietary processing of umbilical cord, cord blood, amniotic membrane, amniotic fluid, and related perinatal materials to create products such as CharaCore, CharaExo, and CharaOmni. Its business appears centered on commercial distribution of regenerative products and provider-facing services rather than a conventional clinical-stage drug-development pipeline. Publicly available FDA materials show the company received an untitled letter in November 2019 and a warning letter dated January 17, 2025 concerning marketing of unapproved biologic products and manufacturing-related compliance issues. Chara Biologics presents itself as an active regenerative medicine and tissue-processing company serving the U.S. market.